Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.
- Read more about FDA accepts application for Roche faricimab for the treatment of neovascular age related macular degeneration and diabetic macular edema
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/fda-accepts-application-for-roche-faricimab-for-the-treatment-of-neovascular-age-related-macular-degeneration-and-diabetic-macular-edema
No comments:
Post a Comment